Drugnews｜藥時事

Team

Two biomedical PhDs translating science into business analysis readers can judge.

Drugnews combines clinical medicine, biotech R&D, business development, and capital-market perspectives. Our goal is to make biotech and pharma content more than news summary: it should become research material readers can inspect, compare, and track.

Drugnews team photo: Dr. Jo-Fan Pan and Dr. Chuan-Sheng Lin
Drugnews｜Dr. Jo-Fan Pan × Dr. Chuan-Sheng Lin
Founder / Editor-in-Chief

Dr. Jo-Fan Pan

PhD, University of Manchester; BSN, National Taiwan University. Former frontline emergency department clinician with experience in pharmaceutical international trade, medical-device distribution, and content entrepreneurship.

  • Specializes in asset value through business development and licensing logic
  • Tracks pharma dealmaking, clinical milestones, and capital-market narratives
  • Leads Drugnews editorial strategy, long-form structure, and reader communication
Partner / Scientific Strategy

Dr. Chuan-Sheng Lin

Biomedical dual-PhD background from Chang Gung University and Europe, with more than 15 years of biotech and pharmaceutical experience across the R&D value chain.

  • Experienced in drug development, technology platforms, patents, and international collaboration
  • Has worked with global pharma companies including Novo Nordisk and Merck
  • Helps the team examine scientific evidence, technical barriers, and development risk

Differentiation

How Drugnews is different

We do not only collect news or make social-media summaries. Drugnews places mechanism, clinical evidence, CMC and regulatory risk, competitive dynamics, licensing, and valuation logic into one judgment framework.

ScienceUnderstand mechanism and evidence
IndustryInterpret R&D and commercialization
CapitalTrack valuation and catalysts